The results demonstrate that transplantation of engineered NSCs, especially those that produce gal-1 with a secretory sequence, conferred robust neuroprotection against stroke by decreasing infarct volume, ameliorating white matter injury, and improving sensorimotor and cognitive functions for at least 28 days after stroke. This evidence concerns the gene LGALS1 and Stroke.